{"name":"Armata Pharmaceuticals, Inc.","slug":"armata-pharmaceuticals-inc","ticker":"","exchange":"","domain":"armata.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"C16G2 Gel","genericName":"C16G2 Gel","slug":"c16g2-gel","indication":"Other","status":"phase_2"},{"name":"C16G2 Rinse","genericName":"C16G2 Rinse","slug":"c16g2-rinse","indication":"Treatment of minor cuts and scrapes","status":"phase_2"},{"name":"C16G2 Varnish","genericName":"C16G2 Varnish","slug":"c16g2-varnish","indication":"Other","status":"phase_2"},{"name":"AP-PA02","genericName":"AP-PA02","slug":"ap-pa02","indication":"Other","status":"phase_2"},{"name":"AP-SA02","genericName":"AP-SA02","slug":"ap-sa02","indication":"Other","status":"phase_1"},{"name":"C16G2 Strip","genericName":"C16G2 Strip","slug":"c16g2-strip","indication":"Other","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AB-PA01","genericName":"AB-PA01","slug":"ab-pa01","indication":"Chronic Pseudomonas aeruginosa respiratory tract infections in cystic fibrosis patients","status":"phase_2"},{"name":"AB-SA01","genericName":"AB-SA01","slug":"ab-sa01","indication":"Treatment of complicated urinary tract infections caused by Gram-negative bacteria","status":"phase_2"}]}],"pipeline":[{"name":"C16G2 Gel","genericName":"C16G2 Gel","slug":"c16g2-gel","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"C16G2 Rinse","genericName":"C16G2 Rinse","slug":"c16g2-rinse","phase":"phase_2","mechanism":"C16G2 Rinse is a topical antimicrobial agent.","indications":["Treatment of minor cuts and scrapes"],"catalyst":""},{"name":"C16G2 Varnish","genericName":"C16G2 Varnish","slug":"c16g2-varnish","phase":"phase_2","mechanism":"C16G2 Varnish is designed to selectively target and eliminate cariogenic bacteria in the oral cavity.","indications":[],"catalyst":""},{"name":"AB-PA01","genericName":"AB-PA01","slug":"ab-pa01","phase":"phase_2","mechanism":"AB-PA01 is a bacteriophage therapeutic that targets and lyses pathogenic bacteria to treat infections.","indications":["Chronic Pseudomonas aeruginosa respiratory tract infections in cystic fibrosis patients"],"catalyst":""},{"name":"AB-SA01","genericName":"AB-SA01","slug":"ab-sa01","phase":"phase_2","mechanism":"AB-SA01 is a novel antimicrobial agent that targets and disrupts bacterial cell membranes.","indications":["Treatment of complicated urinary tract infections caused by Gram-negative bacteria"],"catalyst":""},{"name":"AP-PA02","genericName":"AP-PA02","slug":"ap-pa02","phase":"phase_2","mechanism":"Bacteriophage therapy that uses viruses to selectively infect and destroy pathogenic bacteria.","indications":[],"catalyst":""},{"name":"AP-SA02","genericName":"AP-SA02","slug":"ap-sa02","phase":"phase_1","mechanism":"Bacteriophage therapy that uses viruses to selectively target and destroy Staphylococcus aureus bacteria.","indications":[],"catalyst":""},{"name":"C16G2 Strip","genericName":"C16G2 Strip","slug":"c16g2-strip","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNWVdlRzRIeUpJVDdDTlhDRWtNYWxBeEstZmhYTzc3cVlxUjVWOURUMzBhXzZpWkVkaGR4VUJzTnFRMGdLUmk4TkEySVBvMXJOSUtaWm5INndtVzBpakJzUFVneFpudVNiYTFIRTNibl9qa19JN09KSEZsLURFbFFQb29TSHpNU0hWREhJLW9SYWRkQWFobmx5VWJ3Y3JNMlhJSUJjSlNzRDBpSFJuOF9jVDVn?oc=5","date":"2026-03-12","type":"pipeline","source":"seekingalpha.com","summary":"Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - seekingalpha.com","headline":"Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE16a2M1MnB2R3dBbXhQQjdndEU2U1pOX2NfSjVsVHl2ZVBobzFDRDc4MnZfVjE0dmdkRF9PSTRFZy1lVWNQRkFJNVY3ZklTVnNVY2FCVkJMR3ZHQQ?oc=5","date":"2026-01-01","type":"pipeline","source":"Market.us","summary":"Bacteriophage Market Size, Share, Growth | CAGR of 6.3% - Market.us","headline":"Bacteriophage Market Size, Share, Growth | CAGR of 6.3%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNZFMzWGxoalhCMVVadmNaV3puaEZ1NEVHV3lXMnVvYm94TlFRdWVWWllxTWFHaTRqeGw4bXY0Y0NRVTBfRTZBcWFFSzk2dDNxWTRtUkdzSXAwVkpUdGRqdWVJaFJOQkZmSDRPVEMwckR0T21MeGVodVhZZHJIVDRJZ2tHUVcySExibk9QaWRMZnNFcDFsTG1ka3IxNGE3TmltU1Q0NEp6ZVpJR2o5bUVUUjJZQnpPemlDcTViWHFsVUxaZUJ1Ty1BOWJZQkM1U0l3VXBFZUdNZlc0bmp40gHiAUFVX3lxTE4yY1BZYWxUVGJyQ2VOV3RoTXI3R21vTlBmbVVfaElQY3dNZGduMGw1UDJUTVNFd3ZTTzZaMFZKYURPU3gzV1ZVaEpWTEFKZUhnd0NYQ0lGSks3Y2ZsTW9TWmZnbXUxMUE3YjhnXzg5czd4S28xYXA4QVN6bnBlTjNyME1rMklPdHUtd2pZcDNKZFVnZlo4MmpBejd0VzRPSnZ1cFk0cWsxbDg2bnFHTklOeEYydzE5VzdfdlM1ZEtXLXU1YTNrMUxDWDNicmdFUkRCMTYzREFBcHZkUEtXRFA0bnc?oc=5","date":"2025-10-30","type":"trial","source":"Express Pharma","summary":"Armata AP-SA02 shows promise for SAB in Phase IIa trial, underscoring growing potential of phage therapy: GlobalData - Express Pharma","headline":"Armata AP-SA02 shows promise for SAB in Phase IIa trial, underscoring growing potential of phage therapy: GlobalData","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQN3FOaVB3YllEQnR1czVKX0x5ZmUzNTMxMHFtSkl1YlF3cmJIQzFXVVpvczU0dVFBSDZVYVJJTUhod2xwekpXSXpyVTZNUXhJUXNXY0Y5SDc5dDdseFBhR3VOWjRkaWpYNzdxSEtQeUtMZkJpQmh3Zkd4dHI0NFdrRzRJbllyenFTWDE5VA?oc=5","date":"2025-10-23","type":"pipeline","source":"Yahoo Finance","summary":"Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - Yahoo Finance","headline":"Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNUmFjdVBlcmtEdGduQXREb28xRmhVYkhIeGtXT0JQa0t4RUlNSlFXaXBkY2FraFRVUXVTN2o5a1lPakpfWE9sQVpIVUEwYTdiTUkzTC1zR0dhTWJLRzlXTDlIRGNzQUFmWlctN3U1NHRlR3dFM3pKaEpZV3J4eEVQNEln?oc=5","date":"2025-10-22","type":"trial","source":"seekingalpha.com","summary":"Armata surges on trial data for antibacterial (ARMP:NYSE) - seekingalpha.com","headline":"Armata surges on trial data for antibacterial (ARMP:NYSE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQR2hMczZSNm9ka1BJdWgtbEQxSlh4MS1oNUt1Z0tvdEVWT0FMalk4Y25OQjJEb1hKUFRuUHRZblB1ZzdJSUMtZHhZMTBQTVVtNS1uSzdyUVh3SU4zOS1JMEZfcnFVTm5oY1c2WGRfaXdYSGZXRTgtdmRieWhtMWlOeFNMOFN3WFFyUGNQLUhEcXh4a0JtZVlKLTFoVUxtNjVubmRZVkEwcnh3MHVyM0d4Z3lBRER3Yy1tZGIzaFdkbGV1VE5MS0Z1NmhFNW8xSWNnUzdSekUwUjdfWkZMTUc3UkxOVWlhaktYeFVkVFlsemJqeDFUbU05c0hzLTRTODN1dzdQanpRSmpSazNOZHdWMzZB?oc=5","date":"2025-08-25","type":"pipeline","source":"GlobeNewswire","summary":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight - GlobeNewswire","headline":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPaDBUbDdqM3JTVGpNM0cyRTFhNEhPY2ZKLVVvT09vYk9FSEw2NG9ZcWFLRFFOT3NkR3lhYnRMbXRsNnN6YnZWY0NjcEpIV0QtLXFaX3RySlBJYU5wUVE5cjBnX0c2Wk5RRGJMZXVSektMd2lFNjF4QU5qcDlrbjVnNW0xSS1aa1l3VWplZ2h2ZVlDdnZhLUE1QVV6eXNTUUVUNWZabTdNbHotZDY3ekI3SlgxSWVDS2lF?oc=5","date":"2025-08-19","type":"pipeline","source":"LinkedIn","summary":"JPMorgan downgrades pharma but still likes a few stocks - CNBC TV18 - LinkedIn","headline":"JPMorgan downgrades pharma but still likes a few stocks - CNBC TV18","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPQzdXZm1tUU5HMDFzVlpqTG9pQ0Via044a2QyVDJKUk5KcEJfakNIbkxkVWlZTVd0cU8zQlRzVV9lckpqZnZaWC1uX1dzT25iems4MndKQUhDakVkb2lEZE42Vmc3a21OWExYSEt1bElPTF96REJ4MWJBTzl2RndrcGZaaDJEQnpPcmhzWDUtd2NUUDZCN1lWbVJMbld2NmFFakxqQ3pTZnozQ0Y4b3l6V0IycHNYUExlbVVQYlJmWlZ1VE5PeVR5ZkZJd08xT3BnUGxIeWFIWGpCdmI0eVE?oc=5","date":"2025-05-14","type":"earnings","source":"prnewswire.com","summary":"Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - prnewswire.com","headline":"Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcHB0QUdsZlM4UXNWUEphM2p2Y1F1WXRrNVVxdjhYOWlCT29tNTBNbDNkd19xMnNhSm5tS2xrNHlMd2N0VU0tUWFkWF9pR2NhZnBsMHRTcERhNnFoTndZc09QM2JGVnRjTTVHSWhaQm1kT0l3WTFFWFFLRVcwWVY2YUVNc2tEcHV5UTVlbF8tMzhvWEFDQkg5UktBMnhtWXlGYWZfVk4zSjlGNWxHLWtnSFh6WXZ0ZjNfSUpR?oc=5","date":"2025-01-09","type":"pipeline","source":"BioSpace","summary":"Bacteriophage Therapy Market Size Expected to Reach USD 1,651.8 Million by 2030 - BioSpace","headline":"Bacteriophage Therapy Market Size Expected to Reach USD 1,651.8 Million by 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOeDRLcWhHQzNTcG05OGRudFl2QWx3ckxoaXRaem9xc0tpVXZidURsd3k1emJ5Z0pMdzFNaHVlRWhVbFllMF9yc0JVeXJuTGxmbmdmZWZxX21fcUYtQjVhd2FkaXZpMURiYXpHRFlScGdzQ1FJQmJzTmhBbXR3Qi1XZFRpNA?oc=5","date":"2023-08-22","type":"pipeline","source":"Yahoo Finance","summary":"Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why - Yahoo Finance","headline":"Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOSy1iZFU4Vng4bGlqZWVkOFUxTDhBMERJRnkwc2lGN2czNlg0ODNOdTlVVnU5R0xSeUphSGFCOUdQajRVTjZKZG1aWWNjbFQ3cndFbG1UYjRraFdBQy1wOGdVVk03M2hWbUc5V3dkbm14SV84dWlqWWQwZlpPV2tKVHVWMk56aHk0MnFEc0VvcWszcFJlUHJPX1JEUENVVk5u?oc=5","date":"2022-07-11","type":"deal","source":"BioPharma Dive","summary":"Healthcare asset manager Innoviva buys another biotech at a bargain price - BioPharma Dive","headline":"Healthcare asset manager Innoviva buys another biotech at a bargain price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE9tT3U5eDE5QTQxUDRvbkZsNWktblJQd0VKLUpHZWZhUkVtTG9GVGwyZXhSUlNkRlFjeVRBSmNzWUt5QlROcXBtaw?oc=5","date":"2020-12-13","type":"deal","source":"StockInvest.us","summary":"Armata Pharmaceuticals Stock Price Forecast. Should You Buy ARMP? - StockInvest.us","headline":"Armata Pharmaceuticals Stock Price Forecast. Should You Buy ARMP?","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_2":7,"phase_1":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}